GGrantIndex
← Search

Cancer Genomics Shared Resource

$29,411P30FY2019CANIH

Wake Forest University Health Sciences, Winston-Salem NC

Investigators

Linked publications, trials & patents

Trial NCT07614022Trial NCT07324577Trial NCT07322367Trial NCT07282444Trial NCT07203534Trial NCT07196241Trial NCT07175376Trial NCT07119489Trial NCT07046936Trial NCT06945042Trial NCT06709404Trial NCT06654245Trial NCT06480591Trial NCT06441266Trial NCT06340503Trial NCT05984680Trial NCT05934851Trial NCT05877404Trial NCT05854966Trial NCT05825066Trial NCT05796518Trial NCT05696782Trial NCT05692635Trial NCT05597878Trial NCT05395936Trial NCT05309655Trial NCT05242770Trial NCT05212272Trial NCT05204290Trial NCT05030038Trial NCT04897217Trial NCT04858269Trial NCT04797884Trial NCT04677816Trial NCT04659993Trial NCT04623515Trial NCT04586127Trial NCT04526080Trial NCT04495751Trial NCT04485026Trial NCT04454489Trial NCT04430335Trial NCT04415944Trial NCT04375384Trial NCT04337580Trial NCT04327700Trial NCT04266470Trial NCT04253964Trial NCT04217317Trial NCT04174742Trial NCT04173247Trial NCT04111107Trial NCT04040244Trial NCT04037527Trial NCT03998189Trial NCT03987568Trial NCT03987555Trial NCT03982537Trial NCT03963739Trial NCT03958747Trial NCT03929211Trial NCT03890614Trial NCT03880526Trial NCT03874065Trial NCT03870529Trial NCT03870451Trial NCT03868943Trial NCT03867175Trial NCT03861091Trial NCT03861065Trial NCT03796273Trial NCT03746262Trial NCT03741868Trial NCT03741829Trial NCT03740035Trial NCT03681405Trial NCT03662074Trial NCT03529565Trial NCT03520283Trial NCT03505762Trial NCT03505736Trial NCT03505671Trial NCT03379376Trial NCT03374995Trial NCT03370159Trial NCT03188432Trial NCT03152786Trial NCT03148080Trial NCT03139435Trial NCT03122743Trial NCT03087591Trial NCT03032250Trial NCT02971410Trial NCT02971397Trial NCT02949843Trial NCT02835222Trial NCT02835066Trial NCT02832154Trial NCT02827838Trial NCT02747407

Abstract

CANCER GENOMICS SHARED RESOURCE Project Summary Next-generation sequencing (NGS) and microarray technologies are essential resources for investigating the genomic and molecular underpinnings of cancer formation, progression, and clinical outcomes. The primary objective of the Cancer Genomics Shared Resource (CGSR) is to maximize the scientific and clinical impact of research by Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) members. This is accomplished by providing rapid and cost-effective access to state-of-the-art genomic technologies, while creating a unifying environment that cultivates scientific awareness, education, and collaboration. The CGSR supports the WFBCCC's mission by providing cancer-prioritized access to comprehensive microarray and NGS technologies and offers seamless data flow through to the Biostatistics and Bioinformatics Shared Resource - for bioinformatics support. In October 2014, at the instigation of Director Pasche, the former Microarray Core Laboratory (2002-2014; which received a score of ?excellent? in the prior critique) was renamed the Cancer Genomics Shared Resource to reflect the integration of the WFBCCC's microarray core competencies with the NGS expertise of the Center for Genomics and Personalized Medicine Research. This new joint-Center partnership reflects the strategic plans of the WFBCCC and the Wake Forest School of Medicine (WFSOM), as well as supporting priority recommendations of the WFSOM Centers and Cores Advisory Committee. The CGSR provides cutting-edge genomic services, prioritizes cancer-specific research, creates an optimal environment for the Institution's rapidly developing precision medicine initiative, and seamlessly integrates with other key Shared Resources within the WFBCCC to promote integrated, high-quality workflows for cancer genomics research. The CGSR is led by Co-Directors Lance Miller, Ph.D., and Greg Hawkins, Ph.D., who have established records in cancer genomics research, and is operated by four experienced technicians (two at 100% effort, one at 50% effort and one at 5% effort). A bioinformatician devotes 30% of effort to CGSR daily operations. In the most recent grant year (11/01/14-10/31/15), the CGSR operated at 80-90% FTE utilization to provide 1,144 services to 20 investigators, 75% of which were WFBCCC investigators. Compared to previous years, the CGSR doubled its service output and increased its cancer-specific service output by approximately 50%. The CGSR directly contributes to the scientific achievements of WFBCCC investigators by generating high-quality and cost-effective data that will translate into new discoveries, publications, grant awards, and grant applications. Further development of CGSR's role in supporting the development and productivity of WFBCCC Disease-Oriented Teams and the continued development of seamless workflows across Shared Resources are expected to enhance translational genomics initiatives at the WFBCCC.

View original record on NIH RePORTER →